Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortés, Chris Twelves, Linda T. Vahdat et al.|The Lancet|2011Cited by 1.1k
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I. Haddad, Steven I. Sherman, Martin Schlumberger et al.|Endocrine|2017Cited by 104